Empirical Financial Services LLC d.b.a. Empirical Wealth Management Purchases New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Empirical Financial Services LLC acquired 3,975 shares of Lantheus Holdings, Inc. for approximately $388,000, marking a significant investment in the medical equipment provider.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Lantheus, with an average price target of $131.20.
• Despite previously strong performance, Lantheus reported earnings of $1.53 per share, missing the consensus estimate and showing a slight revenue increase of only 0.8% year-over-year.

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,975 shares of the medical equipment provider's stock, valued at approximately $388,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 116 shares during the period. Hughes Financial Services LLC purchased a new position in Lantheus during the 1st quarter valued at about $81,000. UMB Bank n.a. increased its holdings in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after acquiring an additional 381 shares in the last quarter. Blue Trust Inc. increased its holdings in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after acquiring an additional 633 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after acquiring an additional 298 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of several analyst reports. Truist Financial decreased their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, William Blair reissued a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $131.20.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.00% of the company's stock.

Lantheus Stock Performance

Shares of LNTH traded up $1.17 during midday trading on Tuesday, hitting $72.63. 1,576,172 shares of the stock traded hands, compared to its average volume of 1,082,297. Lantheus Holdings, Inc. has a 1-year low of $69.12 and a 1-year high of $118.21. The firm has a market capitalization of $5.03 billion, a PE ratio of 20.63 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The business's 50 day moving average price is $77.54 and its two-hundred day moving average price is $87.67.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period in the previous year, the company earned $1.69 EPS. The business's revenue for the quarter was up .8% compared to the same quarter last year. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.